Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Metastatic Pancreatic Adenocarcinoma 1Mesothelioma, Malignant 1Lung Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 4pembrolizumab 3Nivolumab 3regorafenib 2fludarabine 2SS1(dsFv)PE38 2Ipilimumab 2Hyperthermic Intraperitoneal Chemotherapy 2Doxorubicin 2Decitabine 2Cisplatin 2tislelizumab 1sodium thiosulfate 1sargramostim 1entinostat 1durvalumab 1cemiplimab 1bemcentinib 1avelumab 1atezolizumab 1alvocidib 1alanosine 1X-Rays 1Tetrahydrouridine 1Tamoxifen 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Referral and Consultation 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Tetrahydrouridine × Gastrointestinal × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡